119 related articles for article (PubMed ID: 20167179)
1. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring.
King AB
J Diabetes Sci Technol; 2010 Jan; 4(1):151-4. PubMed ID: 20167179
[TBL] [Abstract][Full Text] [Related]
2. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
King AB
Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
[TBL] [Abstract][Full Text] [Related]
4. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
[TBL] [Abstract][Full Text] [Related]
5. An analysis of dosing equivalence of insulin detemir and insulin glargine: more evidence?
True MW
J Diabetes Sci Technol; 2010 Jan; 4(1):155-7. PubMed ID: 20167180
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
[TBL] [Abstract][Full Text] [Related]
7. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.
Mehta R; Goldenberg R; Katselnik D; Kuritzky L
Ann Med; 2021 Dec; 53(1):998-1009. PubMed ID: 34165382
[TBL] [Abstract][Full Text] [Related]
8. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
9. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
Dailey G; Admane K; Mercier F; Owens D
Diabetes Technol Ther; 2010 Dec; 12(12):1019-27. PubMed ID: 21128849
[TBL] [Abstract][Full Text] [Related]
10. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
11. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.
Kato T; Tokubuchi I; Muraishi K; Sato S; Kato T; Hara K; Tanaka K; Kaku H; Tajiri Y; Yamada K
Diabetes Res Clin Pract; 2010 Dec; 90(3):e64-6. PubMed ID: 20850885
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.
Bilz S; Flückiger M; Meienberg F; Falconnier C; Keller U; Puder JJ
PLoS One; 2018; 13(8):e0202007. PubMed ID: 30114246
[TBL] [Abstract][Full Text] [Related]
14. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
[TBL] [Abstract][Full Text] [Related]
15. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
16. Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
J Diabetes Investig; 2018 Jan; 9(1):91-99. PubMed ID: 28371461
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
[TBL] [Abstract][Full Text] [Related]
18. Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.
Pscherer S; Dietrich ES; Dippel FW; Neilson AR
Ger Med Sci; 2010 Aug; 8():. PubMed ID: 20725588
[TBL] [Abstract][Full Text] [Related]
19. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
Wallace JP; Wallace JL; McFarland MS
Ann Pharmacother; 2014 Mar; 48(3):361-8. PubMed ID: 24396092
[TBL] [Abstract][Full Text] [Related]
20. Refining basal insulin therapy: what have we learned in the age of analogues?
Devries JH; Nattrass M; Pieber TR
Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
